MedTrace Logo

Influenza Vaccination After Acute Coronary Syndrome

NCT07259252 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6620

Last updated 2026-01-13

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are:

* Whether influenza vaccination can decrease events of cardiovascular death, MI, or stroke?
* Whether influenza vaccination can decrease events of all cause death, unplanned revascularization, unplanned hospitalization for heart failure or for arrhythmia, stent thrombosis?

If there is a comparison group: Researchers will compare influenza vaccination and placebo to see if adverse cardiac events decrease.

Participants will receive an influenza vaccination or placebo after enrollment and phone calls for follow-up at 1 month, 3 months, 6 months and 1 year after discharge.

Conditions

  • Acute Coronary Syndromes (ACS)

Interventions

DRUG

Influenza vaccine

Patients receive injection of 0.5ml influenza vaccine

DRUG

Placebo

Patients will receive injection of 0.5ml PBS

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Dao Wen Wang · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-03
Primary Completion
2029-03-30
Completion
2029-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07259252 on ClinicalTrials.gov